AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Novocure Ltd (NASDAQ:NVCR)
18.57 USD
+0.020 0.108%Sponsored Reports
Loading...
| Previous Close (in USD) | 18.55 |
|---|---|
| Change | +0.020 0.108% |
| 52 W H/L (in USD) | 82.640/10.870 |
| EBITDA (in USD) | -195.609M |
| PE Ratio | -- |
| Volume | 295863 |
| Diluted Eps TTM | -1.81 |
| Total Assets (in USD) | 1146.129M |
|---|---|
| Total Liabilities (in USD) | 783.633M |
| Revenue TTM (in USD) | 525.659M |
| Cash (in USD) | 240.821M |
| Market Cap (in USD) | 2,457.835 M |
| Revenue Per Share TTM | 4.922 |
| Gross Profit TTM (in USD) | 423.584M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Employees: 1453
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. William F. Doyle | Exec. Chairman | 1962 |
| 2. | Mr. Asaf Danziger | Pres, CEO & Director | 1966 |
| 3. | Ms. Ashley Cordova | Chief Financial Officer | 1980 |
| 4. | Mr. Wilhelmus C. M. Groenhuysen | Chief Operating Officer | 1958 |
| 5. | Mr. Pritesh Shah | Chief Commercial Officer | 1978 |
| 6. | Prof. Yoram Palti M.D., Ph.D. | Founder & CTO | 1938 |
| 7. | Mr. Uri Weinberg M.D., Ph.D. | Chief Science Officer | NA |
| 8. | Ms. Ingrid Goldberg | VP of Investor Relations | NA |
| 9. | Mr. Barak Ben Arye | Gen. Counsel | NA |
| 10. | Mr. William Patrick Burke | Chief HR Officer | 1955 |
Peers
Sector: Healthcare
Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ABT
Abbott Laboratories |
-1.290 0.997% | 129.27 | 37.150 | 23.148 | 4.666 | 4.975 | 4.878 | 19.381 |
|
SYK
Stryker Corporation |
+2.380 0.659% | 360.6 | 44.070 | 24.938 | 5.509 | 6.118 | 6.050 | 25.731 |
|
MDT
Medtronic PLC |
-0.320 0.380% | 84.41 | 26.600 | 15.873 | 3.354 | 2.083 | 3.897 | 14.117 |
|
BSX
Boston Scientific Corp |
+0.475 0.470% | 101.39 | 68.170 | 24.570 | 5.855 | 4.265 | 6.462 | 26.799 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -81.846M | -52.075M | 18.102M | -8.824M | -45.942M |
| Minority Interest | - | - | - | - | - |
| Net Income | -92.534M | -58.351M | 19.808M | -7.23M | -63.559M |
| Selling General Administrative | 132.753M | 126.127M | 107.437M | 87.948M | 73.456M |
| Gross Profit | 422.973M | 420.154M | 387.865M | 262.712M | 168.021M |
| Reconciled Depreciation | 10.624M | 10.251M | 9.15M | 8.46M | 9.006M |
| Ebit | -100.147M | -54.584M | 21.251M | -9.374M | -42.678M |
| Ebitda | -89.523M | -44.333M | 30.401M | -0.914M | -33.672M |
| Depreciation And Amortization | 10.624M | 10.251M | 9.15M | 8.46M | 9.006M |
| Operating Income | -89.523M | -44.333M | 21.251M | -0.914M | -33.672M |
| Other Operating Expenses | 627.363M | 579.364M | 463.965M | 352.232M | 281.741M |
| Interest Expense | 3.334M | 3.44M | 13.147M | 13.718M | 13.491M |
| Tax Provision | 10.688M | 6.276M | -1.706M | -1.594M | 17.617M |
| Interest Income | 10.961M | 0.791M | 1.787M | 4.402M | 2.652M |
| Net Interest Income | 11.2M | -3.71M | -14.947M | -7.479M | -11.872M |
| Income Tax Expense | 10.688M | 6.276M | -1.706M | -1.594M | 17.617M |
| Total Revenue | 537.84M | 535.031M | 494.366M | 351.318M | 248.069M |
| Total Operating Expenses | 512.496M | 464.487M | 357.464M | 263.626M | 201.693M |
| Cost Of Revenue | 114.867M | 114.877M | 106.501M | 88.606M | 80.048M |
| Total Other Income Expense Net | 7.677M | -7.742M | -3.149M | -7.91M | -0.398M |
| Net Income From Continuing Ops | -92.534M | -58.351M | 19.808M | -7.23M | -63.559M |
| Net Income Applicable To Common Shares | -92.534M | -58.351M | 19.808M | -7.23M | -63.559M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 1146.129M | 1191.648M | 1139.495M | 1051.983M | 479.448M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 8.527M | 6.703M | 0.807M | 11.499M | 0.001M |
| Total Liab | 783.633M | 750.478M | 729.001M | 575.457M | 261.658M |
| Total Stockholder Equity | 362.496M | 441.17M | 410.494M | 476.526M | 217.79M |
| Other Current Liab | -16.224M | -18.028M | -17.762M | 42.2M | -0.001M |
| Common Stock | - | - | - | - | - |
| Capital Stock | 0M | 0M | 0M | 0M | 0M |
| Retained Earnings | -985.503M | -778.46M | -685.926M | -631.077M | -650.885M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 11.161M | 12.086M | 10.908M | 4.904M |
| Cash | 240.821M | 115.326M | 208.802M | 234.674M | 177.321M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 179.115M | 158.777M | 142.602M | 113.612M | 86.311M |
| Current Deferred Revenue | 16.224M | 18.028M | 17.762M | 17.765M | 11.773M |
| Net Debt | 355.421M | 468.945M | 366.411M | 209.524M | -13.757M |
| Short Term Debt | 84.724M | 73.58M | 70.002M | - | 37.614M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 596.242M | 584.271M | 575.213M | 444.198M | 163.564M |
| Other Stockholder Equity | 1353.468M | 1222.063M | 1099.589M | 1111.435M | 871.442M |
| Property Plant Equipment | - | 32.678M | 53.883M | 11.395M | 34.597M |
| Total Current Assets | 1034.409M | 1111.529M | 1073.526M | 999.441M | 439.947M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 669.795M | 854.099M | 728.898M | 607.902M | 148.769M |
| Net Receivables | 77.114M | 112.22M | 110.592M | 117.944M | 88.061M |
| Long Term Debt | 568.822M | 565.509M | 562.216M | 429.905M | 149.424M |
| Inventory | 38.152M | 29.376M | 24.427M | 27.422M | 23.701M |
| Accounts Payable | 94.391M | 85.197M | 72.6M | 53.647M | 36.925M |
| Accumulated Other Comprehensive Income | -5.469M | -2.433M | -3.169M | -3.832M | -2.767M |
| Non Currrent Assets Other | 14.022M | 11.161M | 12.086M | 10.908M | 4.904M |
| Non Current Assets Total | 111.72M | 80.119M | 65.969M | 52.542M | 39.501M |
| Capital Lease Obligations | 27.42M | 18.762M | 12.997M | 14.293M | 14.14M |
| Long Term Debt Total | - | 565.509M | 562.216M | 429.905M | 149.49M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -139.957M | -120.664M | -457.879M | -41.182M | 1.218M |
| Total Cashflows From Investing Activities | -139.957M | -144.834M | -472.847M | -51.667M | -5.493M |
| Total Cash From Financing Activities | 15.491M | 25.702M | 440.209M | 61.681M | 69.369M |
| Net Income | -92.534M | -58.351M | 19.808M | -7.23M | -63.559M |
| Change In Cash | -93.775M | -36.564M | 66.757M | 36.66M | 62.038M |
| Begin Period Cash Flow | 209.609M | 246.173M | 179.416M | 142.756M | 80.718M |
| End Period Cash Flow | 115.834M | 209.609M | 246.173M | 179.416M | 142.756M |
| Total Cash From Operating Activities | 30.788M | 82.756M | 99.148M | 26.62M | -1.865M |
| Depreciation | 10.624M | 10.251M | 9.15M | 8.46M | 9.006M |
| Other Cashflows From Investing Activities | - | - | - | -41.182M | -3.795M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -4.342M | 2.483M | -2.935M | -1.159M | -0.529M |
| Sale Purchase Of Stock | 15.519M | 25.728M | 31.798M | 61.712M | 20.303M |
| Other Cashflows From Financing Activities | 10.295M | 21.182M | 586.867M | 59.245M | 167.618M |
| Capital Expenditures | 21.358M | 24.17M | 14.968M | 10.485M | 6.711M |
| Change In Working Capital | 11.796M | 29.069M | -8.521M | -24.332M | 11.413M |
| Other Non Cash Items | -6.053M | 3.007M | 3.26M | -2.175M | 1.022M |
| Free Cash Flow | 9.43M | 58.586M | 84.18M | 16.135M | -8.576M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Growth Compy Commingled Pl O | 1 year ago | 7381537 |
| 2. | Fidelity Growth Company Fund | 1 year ago | 5294456 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 11 months ago | 3414568 |
| 4. | American Funds Growth Fund of Amer A | 1 year ago | 3302638 |
| 5. | Capital Group Growth Fnd of Amer Comp | 1 year ago | 3302638 |
| 6. | Capital Group AMCAP Composite | 1 year ago | 3074852 |
| 7. | VA CollegeAmerica Amcap 529A | 1 year ago | 3074852 |
| 8. | American Funds SMALLCAP World A | 1 year ago | 3046105 |
| 9. | Vanguard Small Cap Index | 11 months ago | 2724378 |
| 10. | Fidelity Growth Company K6 | 1 year ago | 1834465 |
| 11. | T. Rowe Price Health Sciences | 1 year ago | 1750715 |
| 12. | Fidelity Series Growth Company | 1 year ago | 1541674 |
| 13. | Vanguard Institutional Extnd Mkt Idx Tr | 11 months ago | 1460763 |
| 14. | Vanguard Small Cap Growth Index Inv | 11 months ago | 1359146 |
| 15. | American Funds IS® Growth 1 | 1 year ago | 1183355 |
| 16. | Capital Group Growth Composite | 1 year ago | 1183355 |
| 17. | BlackRock Global Equity Mkt Netrl Instl | 11 months ago | 770231 |
| 18. | iShares Biotechnology ETF | 11 months ago | 717548 |
| 19. | CS (Lux) Digital Health Equity SB USD | 1 year ago | 680000 |
| 20. | Baillie Gifford Global Discovery A Acc | 1 year ago | 659471 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | FMR Inc | 1 year ago | 15962767 |
| 2. | Vanguard Group Inc | 1 year ago | 10023981 |
| 3. | Capital Research & Mgmt Co - Division 3 | 1 year ago | 8864092 |
| 4. | BlackRock Inc | 1 year ago | 8792035 |
| 5. | State Street Corporation | 1 year ago | 3863549 |
| 6. | T. Rowe Price Associates, Inc. | 1 year ago | 2378940 |
| 7. | Capital World Investors | 1 year ago | 2308215 |
| 8. | Baillie Gifford & Co Limited. | 1 year ago | 1990375 |
| 9. | Two Sigma Advisers, LLC | 1 year ago | 1634500 |
| 10. | Geode Capital Management, LLC | 1 year ago | 1591963 |
| 11. | Nordwand Advisors LLC | 1 year ago | 1515000 |
| 12. | Two Sigma Investments LLC | 1 year ago | 1470464 |
| 13. | Morgan Stanley - Brokerage Accounts | 1 year ago | 1418484 |
| 14. | Millennium Management LLC | 1 year ago | 1223362 |
| 15. | NORGES BANK | 1 year ago | 974050 |
| 16. | D. E. Shaw & Co LP | 1 year ago | 953912 |
| 17. | Credit Suisse First Boston (CSFB) | 1 year ago | 847520 |
| 18. | Frontier Capital Management CO Inc | 1 year ago | 793474 |
| 19. | Qube Research & Technologies | 1 year ago | 773831 |
| 20. | Bank of America Corp | 1 year ago | 678612 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
